Matica Biotechnology, the US subsidiary of CHA Biotech, has revealed plans to significantly expand its cell and gene therapy (CGT) CDMO orders, distinguishing itself from most antibody production-based CDMOs in Korea. During a press conference at the Bio International Convention in San Diego, Matica Bio CEO Paul Kim highlighted the anticipated growth in the CDMO market driven by increasing demand and potential for CGT. He also emphasized the company's compliance with the US government's BioSecure Act and its strategic positioning to secure more contracts in the future. Matica Bio's focus on targeting developers aligned with its strategies and pipelines reflects its intention to capitalize on the specialized nature of CGT production. The company's confidence in providing comprehensive CGT solutions tailored to individual patients, combined with its expansion plans in the US, aligns with the projected growth of the global CGT market, driven by an increasing number of CGTs receiving drug authorization. With the US FDA approving several CGTs, the demand for CDMOs is expected to rise, presenting significant opportunities for Matica Bio's expansion and market positioning.